Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antidepressant safety labeling impact

Executive Summary

A Medco study finds that less than 15% of patients on antidepressants receive the FDA recommended level of follow-up care in first four weeks of treatment, 18% at eight weeks and 23% at 12 weeks. The findings, which appear in the August issue of the American Journal of Managed Care, reviewed 84,500 pediatric and adult patients who started a new course of antidepressant therapy between July 2001 and September 2003. The study revealed that 66% of children and 83% of adults had no follow-up visits during the first month of treatment; FDA recommends weekly in-person visits with a health practitioner during that period. FDA required the antidepressant class to add a "black box" warning on suicidality in 2005 (1"The Pink Sheet" Jan. 17, 2005, p. 3)....
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS047459

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel